AVRO Stock Overview
AVROBIO, Inc., a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 1/6 |
Past Performance | 2/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
AVROBIO, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.19 |
52 Week High | US$1.70 |
52 Week Low | US$0.57 |
Beta | 1.24 |
1 Month Change | -2.46% |
3 Month Change | -9.85% |
1 Year Change | 33.71% |
3 Year Change | -89.66% |
5 Year Change | -93.53% |
Change since IPO | -96.19% |
Recent News & Updates
Recent updates
Avrobio rises as gene therapy for Gaucher disease gets ILAP designation in UK
Oct 18Avrobio stock rises as kidney disease gene therapy gets FDA rare pediatric disease status
Sep 20AVROBIO granted FDA’s orphan drug designation for metabolic disorder therapy
Jul 13Here's Why We're Watching AVROBIO's (NASDAQ:AVRO) Cash Burn Situation
Nov 13We're Keeping An Eye On AVROBIO's (NASDAQ:AVRO) Cash Burn Rate
Aug 10AVROBIO: Fabrazyme's Full Approval Changes Things
May 05Here's Why We're Not Too Worried About AVROBIO's (NASDAQ:AVRO) Cash Burn Situation
Mar 08AVROBIO: Undercovered Gene Therapy Developer With Excellent Promise
Dec 25We Think AVROBIO (NASDAQ:AVRO) Can Afford To Drive Business Growth
Nov 23AVROBIO readies $75M equity offering
Nov 19AVROBIO EPS misses by $0.19
Nov 05Shareholder Returns
AVRO | US Biotechs | US Market | |
---|---|---|---|
7D | -2.5% | 1.0% | 1.2% |
1Y | 33.7% | 0.7% | 24.9% |
Price Volatility
AVRO volatility | |
---|---|
AVRO Average Weekly Movement | 6.4% |
Biotechs Industry Average Movement | 11.6% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.6% |
10% least volatile stocks in US Market | 3.0% |
Volatility Over Time: AVRO's weekly volatility has decreased from 15% to 6% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2015 | 13 | Erik Ostrowski | www.avrobio.com |
AVROBIO, Inc., a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company’s pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trials for the treatment of Fabry disease; and AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease.
AVROBIO, Inc. Fundamentals Summary
AVRO fundamental statistics | |
---|---|
Market cap | US$54.28m |
Earnings (TTM) | US$12.16m |
Revenue (TTM) | n/a |
4.4x
P/E Ratio0.0x
P/S RatioIs AVRO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
AVRO income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | -US$12.16m |
Earnings | US$12.16m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 0.27 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did AVRO perform over the long term?
See historical performance and comparison